Elon Musk GLP-1: What He Said About Wegovy and Weight-Loss Medication

What Elon Musk Actually Said About GLP-1 Medication

Musk's public disclosure was brief and specific. In October 2022, responding to a question on X about how he had changed his appearance, he wrote that he was using Wegovy and fasting. He named the drug by brand name. No ghost-writing or spokesperson was involved. The statement came directly from his verified account, which means it functions as a primary source for journalistic purposes.

He later added that he no longer felt the "joy of eating," which is a phrasing that tracks closely with the appetite-suppression mechanism that GLP-1 receptor agonists produce through hypothalamic signaling and slowed gastric emptying. That clinical detail, offered casually in a public thread, gave the disclosure unusual medical specificity compared with most celebrity weight-loss comments.

Why the Wording Matters Clinically

When a public figure names a prescription drug by brand and describes a physiological effect consistent with that drug's known mechanism, clinicians take the statement more seriously than a vague reference to "a new injection." Musk's description of reduced food enjoyment aligns with documented GLP-1 effects on the mesolimbic reward system. A 2022 review published in Nature Reviews Drug Discovery confirmed that GLP-1 receptors are expressed in the ventral tegmental area and nucleus accumbens, areas central to food reward behavior [1].

What He Did Not Say

He did not disclose his starting weight, his BMI, his prescribing physician, his dose titration schedule, or his duration of use at the time of the post. Those omissions matter. Wegovy is FDA-approved only for adults with a BMI of 30 or higher, or a BMI of 27 or higher with at least one weight-related condition such as type 2 diabetes, hypertension, or dyslipidemia [2]. Whether Musk met those criteria at the time is not publicly known, and this article does not speculate.

What Wegovy (Semaglutide 2.4 mg) Is and How It Works

Wegovy is a once-weekly subcutaneous injection of semaglutide at 2.4 mg, manufactured by Novo Nordisk. Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist. It mimics endogenous GLP-1, a hormone secreted from L-cells in the small intestine in response to food intake.

The drug acts through at least three overlapping pathways. First, it slows gastric emptying, meaning food stays in the stomach longer and the sensation of fullness persists. Second, it signals the hypothalamus to reduce hunger drive. Third, as noted above, it modulates reward signaling in dopaminergic circuits, which is likely why Musk described reduced pleasure from eating [1].

The STEP Trial Program: Core Efficacy Data

The Semaglutide Treatment Effect in People with Obesity (STEP) program is the registration trial series Novo Nordisk used to secure FDA approval. These are the numbers clinicians reference when counseling patients.

STEP-1 (N=1,961) enrolled adults with a BMI of 30 or higher, or 27 or higher with a comorbidity, and randomized them 2:1 to semaglutide 2.4 mg or placebo, both with lifestyle intervention. At 68 weeks, the semaglutide group achieved a mean weight loss of 14.9% versus 2.4% in the placebo group (P<0.001) [3]. The proportion of participants losing at least 5% of body weight was 86.4% in the semaglutide arm versus 31.5% with placebo [3].

STEP-2 (N=1,210) focused on adults with type 2 diabetes. Mean weight loss was 9.6% with semaglutide 2.4 mg versus 3.4% with placebo at 68 weeks [4]. Glycemic improvement was substantial, with HbA1c declining by a mean of 1.6 percentage points in the semaglutide arm [4].

STEP-4 examined what happens when patients stop. After 20 weeks of semaglutide treatment, participants randomized to placebo for a further 48 weeks regained two-thirds of their prior weight loss [5]. This underscores that GLP-1 therapy manages obesity rather than curing it.

FDA Approval and Prescribing Criteria

The FDA approved Wegovy on June 4, 2021, under NDA 215256 [2]. The label specifies initiation at 0.25 mg weekly for four weeks, with incremental dose escalation over 16 weeks to reach the 2.4 mg maintenance dose. The slow titration is specifically designed to reduce gastrointestinal side effects during the adjustment period.

The prescribing information lists the following approved indications: chronic weight management in adults with an initial BMI of 30 or higher, or 27 or higher in the presence of at least one weight-related comorbidity [2]. Off-label use outside those parameters is not supported by the STEP registration data.

Side Effects Musk's Comment Hints At, and What the Trials Show

Musk's remark about losing the "joy of eating" is colloquial. Clinically, it reflects two documented effects: anorexia (reduced appetite) and altered food reward, both of which are listed in the Wegovy prescribing information and extensively documented in the STEP program [2].

Gastrointestinal Effects

The most common adverse events across STEP-1 through STEP-4 were gastrointestinal. In STEP-1, nausea occurred in 44% of semaglutide participants versus 16% of placebo participants [3]. Vomiting affected 24.5% versus 6.8%, and diarrhea 29.7% versus 15.9% [3]. The majority of these events were mild to moderate and occurred predominantly during the dose-escalation phase. Serious gastrointestinal events, including pancreatitis, occurred in less than 1% of participants but represent a labeled warning [2].

Thyroid C-Cell Considerations

The Wegovy label carries a black-box warning for thyroid C-cell tumors, based on rodent carcinogenicity studies. Human relevance has not been established. The FDA requires that prescribers and patients discuss this risk, and the drug is contraindicated in individuals with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 [2].

Cardiovascular Signal

The SELECT trial (N=17,604), published in the New England Journal of Medicine in 2023, showed that semaglutide 2.4 mg reduced major adverse cardiovascular events by 20% versus placebo in adults with established cardiovascular disease and overweight or obesity without diabetes (hazard ratio 0.80; 95% CI 0.72 to 0.90; P<0.001) [6]. This was a landmark finding. The drug's benefit extended well beyond weight reduction.

GLP-1 Drugs as a Drug Class: Context Beyond Musk

Musk's disclosure occurred as semaglutide was transitioning from a diabetes medication to a widely discussed weight-loss drug. The broader GLP-1 class includes several agents with different dosing schedules, routes of administration, and approved indications.

Semaglutide Formulations

Ozempic (semaglutide 0.5 mg, 1.0 mg, 2.0 mg) is FDA-approved for type 2 diabetes management and, separately, for cardiovascular risk reduction in adults with type 2 diabetes and established cardiovascular disease [7]. It is not FDA-approved for chronic weight management, though it is frequently prescribed off-label for that purpose. Wegovy uses the same molecule at a higher weekly dose (2.4 mg) with the weight-management indication.

Rybelsus (oral semaglutide 7 mg, 14 mg) is FDA-approved for type 2 diabetes. Oral bioavailability is approximately 1% of the injected equivalent, which explains the lower effective doses [8].

Tirzepatide (Zepbound / Mounjaro)

Tirzepatide, sold as Zepbound for obesity and Mounjaro for type 2 diabetes, targets both GLP-1 and GIP receptors. The SURMOUNT-1 trial (N=2,539) reported mean weight loss of 20.9% at 72 weeks with the 15 mg dose versus 3.1% with placebo [9]. The FDA approved Zepbound for chronic weight management in November 2023 [10]. Tirzepatide was not the drug Musk referenced, but it has since become a significant competitor in the same therapeutic space.

What Clinicians Say About Public Figures and Drug Disclosure

Public figures naming prescription drugs by brand can shift patient behavior at scale. A framework the HealthRX medical team uses when patients present citing celebrity use:

Step 1. Confirm indication. Does the patient meet the FDA-approved BMI threshold (30, or 27 with a comorbidity)? [2] A celebrity's physique at any given moment does not establish that they met criteria when starting. Prescribing outside indication for weight loss is legal but shifts liability to the prescriber and lacks the safety data of the approved population.

Step 2. Rule out contraindications. Personal or family history of medullary thyroid carcinoma, MEN2, pregnancy, and severe gastrointestinal disease all appear in the Wegovy label as contraindications or precautions [2].

Step 3. Set realistic expectations. STEP-1 showed 14.9% mean weight loss at 68 weeks [3]. That is a population average. Individual response varies, and roughly 14% of STEP-1 participants lost less than 5% of body weight on active drug [3]. Patients who hear about a celebrity's transformation may anchor to a best-case outcome.

Step 4. Discuss the discontinuation data. STEP-4 showed that stopping semaglutide results in substantial weight regain within one year [5]. Patients need to understand this is long-term management, not a short course.

Step 5. Address cost and access. Wegovy's list price exceeds $1,300 per month in the United States as of 2025. Insurance coverage varies widely. Generic semaglutide is not yet available from the brand manufacturer, though FDA-authorized compounders offered compounded semaglutide during the shortage period that ended in 2024 [11].

The Endocrine Society's 2023 clinical practice guideline on obesity pharmacotherapy states: "Clinicians should use anti-obesity medications as an adjunct to lifestyle intervention in patients with BMI ≥30 kg/m² or BMI ≥27 kg/m² with at least one obesity-related comorbidity" [12]. That framing, adjunct not replacement, is the clinical context Musk's social media post lacked.

Intermittent Fasting Combined With GLP-1: What the Evidence Shows

Musk cited fasting alongside Wegovy. Combining caloric restriction strategies with GLP-1 therapy is common in clinical practice, though the specific interaction of intermittent fasting with semaglutide has not been tested in a dedicated randomized controlled trial as of mid-2025.

Additive Appetite Suppression

Both intermittent fasting and GLP-1 receptor agonism reduce energy intake, but through different mechanisms. Fasting lowers insulin and raises glucagon, promoting fat oxidation. Semaglutide reduces gastric emptying and appetite signaling independently of meal timing. The combination could produce additive suppression of energy intake, though whether that translates to superior weight loss without added risk of inadequate nutrition has not been rigorously studied [13].

Muscle Mass Considerations

A concern raised by obesity specialists is that rapid weight loss from GLP-1 therapy, particularly when combined with severe caloric restriction, may accelerate lean mass loss. A 2023 analysis in Obesity found that roughly 40% of weight lost on semaglutide in the STEP-1 trial was lean mass, though that estimate was based on modeling rather than direct DEXA measurement in all participants [14]. Resistance training is commonly recommended alongside GLP-1 therapy to mitigate this. Musk has not publicly commented on his exercise regimen in this context.

The Broader Significance of Musk's Disclosure

Celebrity medication disclosure is not new, but the scale and speed at which Musk's 2022 post circulated was unusual. Search interest for "Wegovy" and "semaglutide" spiked substantially in the days following the post, according to Google Trends data from that period. Novo Nordisk reported supply constraints throughout 2022 and 2023, driven partly by demand that outpaced manufacturing capacity [15].

The FDA placed Wegovy on its drug shortage list in March 2022, several months before Musk's post, and the shortage persisted into 2024 [11]. Clinicians were already managing access challenges before celebrity discourse amplified demand further.

What This Means for Patients

The primary clinical concern with celebrity-driven drug interest is selection pressure. Patients who request a specific drug by name may have self-diagnosed their eligibility based on a public figure's silhouette rather than a clinical workup. The appropriate path remains: a formal weight history, metabolic panel, assessment of comorbidities, and a shared decision with a licensed prescriber about whether GLP-1 therapy is appropriate.

Musk's willingness to name the drug, describe a physiological effect, and pair it with a behavioral intervention (fasting) was more clinically substantive than most celebrity health disclosures. That does not make it a medical recommendation. It makes it a data point.